Drug
Shr2285
Shr2285: highest development phase Phase 1, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| SHR2285 tablet NCT04472819 | Phase 1 | Thrombosis |
Latest
No recent events.
Follow Shr2285 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.